Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

Also called NCT01452815

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 201 participants (enrolled count) (from the registry)
Sponsor
Tranzyme, Inc. (from the registry)
Registry
  • NCT NCT01452815
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Belgium, Denmark, Finland, Germany, Norway, Poland, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01452815. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2012-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Condition
Gastroparesis
Condition
Diabetes Mellitus, Type 1
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
10mg TZP-102
Intervention (Drug)
20mg TZP-102
Lead sponsor
Tranzyme, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01452815
Content hash
1beca1760016de97b569dfb5e31100d963e26b0f6b144a151e616f63eb147d05